September 10, 2024
PRESS RELEASE

MultiplexDX at ESMO 2024: Representing Slovak innovation in oncology

This year, we had the honor of attending our third major conference, the ESMO 2024 Congress in Barcelona, the largest oncology conference in Europe. Organized by the European Society for Medical Oncology, this prestigious event brings together top oncologists, pathologists, and researchers to share groundbreaking advances and shape the future of cancer care.

For us at MultiplexDX, this year’s ESMO was particularly special. A team of 17 of our scientists joined the conference—the largest delegation in our company’s history. It was an amazing opportunity for our team to immerse themselves in cutting-edge oncology research, attend inspiring talks by global leaders, and gain invaluable insights to bring back to our lab.

We also proudly presented a poster on our Multiplex8+ test for breast cancer patients, showcasing how our innovation helps determine the efficacy of treatments like Kadcyla®. It’s a privilege to demonstrate that Slovak science can stand alongside the best in the world.

For more information, read full abstract here: https://oncologypro.esmo.org/meeting-resources/esmo-congress-2024/development-and-validation-of-a-19-feature-classifier-that-predicts-response-to-neoadjuvant-trastuzumab-emtansine-t-dm1-in-breast-cancer-patients.

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News